Ionis Pharmaceuticals has discontinued an early investigational Alzheimer's treatment in people with Down syndrome, representing another setback for a high-risk, underserved patient group.
Longevity News
Ionis Pharmaceuticals has pulled the plug on an early investigational treatment for Alzheimer’s disease in people wit...
Source: FierceBiotech - All • Published: 20 Feb 2026, 21:00
Continue exploring
Related longevity signals
Longevity TechnologyIonis, Biogen deliver new tau data in Alzheimer’sThis article previews a news piece about new clinical trial results for a tau-targeting Alzheimer’s therapy, highlighting study type and implications for the field.Longevity TechnologyRetro Biosciences expands early trial for drug targeting Alzheimer’s, Parkinson’sA short news article about an early-stage clinical trial expansion testing higher doses of a candidate neurodegenerative drug, outlining safety and dosing goals and what readers can expect to learn.PR NewswireFibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc DiseaseA biotech news article about a newly accepted patent application describing a proposed CBD-plus-fibroblast approach for treating degenerative spinal discs, inviting readers to learn how the company frames this combined therapy and its potential pathway.Frontiers - HealthThe Application Progress of Artificial Intelligence in the Diagnosis of Alzheimer's DiseaseSurvey of how machine learning and deep learning are being applied to neuroimaging and multi-omics for earlier, automated Alzheimer's diagnosis and staging.